Planned sale of 6,165 Neumora (NASDAQ: NMRA) shares under Rule 144

Rhea-AI Filing Summary

Neumora Therapeutics (NMRA) had a security holder file a notice of proposed sale of 6,165 shares of common stock under Rule 144. The planned sale, through Merrill Lynch on NASDAQ around 02/17/2026, had an aggregate market value of $21,916.58 at the time of the notice.

The shares come from a restricted stock unit award that vested on 02/14/2026 and was granted as part of the issuer’s equity compensation plan. Neumora had 167,089,114 shares of common stock outstanding, which is a baseline figure for the company’s total equity.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	6165	21916.58	167089114	02/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/14/2026	Vesting of restricted stock unit award	Neumora Therapeutics, Inc.			6165	02/14/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Neumora Therapeutics (NMRA) Form 144 filing disclose?

The filing discloses a proposed sale of 6,165 Neumora common shares under Rule 144. The shares were recently acquired through a vested restricted stock unit award from the company’s equity compensation plan and are planned to be sold on NASDAQ through Merrill Lynch.

How many Neumora Therapeutics (NMRA) shares are proposed to be sold?

The security holder plans to sell 6,165 shares of Neumora common stock. These shares were acquired on 02/14/2026 via vesting of a restricted stock unit award granted under the issuer’s equity compensation plan, according to the Rule 144 notice.

What is the aggregate market value of NMRA shares in this Form 144?

The proposed 6,165-share sale has an aggregate market value of $21,916.58. This value reflects the market pricing used in the notice and helps indicate the approximate dollar size of the intended Rule 144 transaction in Neumora common stock.

When were the Neumora (NMRA) shares acquired and how?

The shares were acquired on 02/14/2026 through the vesting of a restricted stock unit award. The award was granted by Neumora Therapeutics, Inc. as part of its equity compensation plan, and the vesting created the 6,165 common shares to be sold.

When is the Neumora (NMRA) Rule 144 sale expected to occur?

The notice lists an approximate sale date of 02/17/2026 for the 6,165-share transaction. The planned sale will be executed through Merrill Lynch on the NASDAQ exchange, consistent with the routing and venue information provided in the Rule 144 filing.

How many Neumora (NMRA) shares are outstanding compared to this sale?

Neumora had 167,089,114 shares of common stock outstanding. This figure represents the company’s total common equity base and serves as a baseline reference against which the proposed 6,165-share Rule 144 sale can be viewed in relative size terms.